Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Corvus Pharmaceuticals (CRVS) Accumulated Depreciation & Amortization (2022 - 2025)

Corvus Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 4 years, most recently at $28000.0 for Q3 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $28000.0 for Q3 2025, down 56.92% from a year ago — trailing twelve months through Sep 2025 was $28000.0 (down 56.92% YoY), and the annual figure for FY2024 was $100000.0, down 50.0%.
  • Accumulated Depreciation & Amortization for Q3 2025 was $28000.0 at Corvus Pharmaceuticals, down from $51000.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CRVS hit a ceiling of $4.3 million in Q1 2022 and a floor of $21000.0 in Q2 2024.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $65000.0 (2024), compared with a mean of $386266.7.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: tumbled 98.69% in 2023 and later soared 142.86% in 2025.
  • Corvus Pharmaceuticals' Accumulated Depreciation & Amortization stood at $400000.0 in 2022, then crashed by 50.0% to $200000.0 in 2023, then crashed by 50.0% to $100000.0 in 2024, then crashed by 72.0% to $28000.0 in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $28000.0 (Q3 2025), $51000.0 (Q2 2025), and $22000.0 (Q1 2025) per Business Quant data.